Chao Zhou Net Worth

Chao Zhou biography

Chao Zhou serves as Director of the Company. Mr. Chao Zhou is currently the Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited, a public company listed on the Hong Kong stock exchange that develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations with significant experience in R&D and product commercialization in China. Since 2018, Mr. Zhou has served on the Board of Directors of Grand Pharma Sphere Pty Ltd, a Singapore based company that indirectly wholly-owns the Australian based global medical device company, Sirtex Medical Pty. Ltd. Prior to his role as Executive Deputy Officer, Mr. Zhou served as a Management Director in the Department of Legal Security for China Grand Enterprises, Inc., an investment company engaged in the operation and management of businesses covering pharmaceuticals and healthcare, commodity trading, real estate investment, financial service and other sectors. He earned his Bachelor in Law from Ocean University of China and a Master in International Law from the University of International Business and Economics.

How old is Chao Zhou?

Chao Zhou is 31, he's been the Director of OncoSec Medical Inc since 2020. There are 11 older and no younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.

What's Chao Zhou's mailing address?

Chao's mailing address filed with the SEC is 24, North Main Street, Pennington, Mercer County, New Jersey, 08534, United States of America.

Insiders trading at OncoSec Medical Inc

Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha и Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.

What does OncoSec Medical Inc do?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

OncoSec Medical Inc executives and stock owners

OncoSec Medical Inc executives and other stock owners filed with the SEC include:

• Daniel O'Connor,
  President, Chief Executive Officer, Director
• Robert J. DelAversano CPA,
  VP of Fin. and Principal Accounting Officer & Controller
• Margaret Dalesandro,
  Independent Chairman of the Board
• Herbert Lyerly,
  Independent Director
• Chao Zhou,
  Director
• Yuhang Zhao,
  Director
• Kevin Smith,
  Director
• Robert DelAversano,
  Principal Accounting Officer, Controller
• Robert Ward,
  Independent Director
• James DeMesa,
  Independent Director
• Joon Kim,
  Director
• Dr. Mai Hope Le M.D.,
  Consultant
• Dr. Sandra Aung Ph.D.,
  Sr. VP & Chief Clinical Devel. Officer
• Tu Diep M.Sc.,
  Sr. VP & Head of Operations
• Dr. Kim Jaffe,
  Assistant VP of Bus. Devel. & Operations
• Robert Hamilton Pierce,
  Chief Medical Officer
• Sheela Mohan Peterson,
  Chief Legal Officer
• Sharron E Gargosky,
  Chief Clinical & Reg. Officer
• Anthony E Iii Maida,
  Director
• Mai Hope Le,
  Chief Medical Officer
• Richard B Slansky,
  Chief Financial Officer
• Avtar S Dhillon,
  Director
• Punit Dhillon,
  President and CEO
• Annalisa Jenkins,
  Director
• Gregory T. Mayes,,
  Director
• Sara Bonstein,
  CFO/COO
• Spahr Stephany Foster,
  Director
• Veronica Vallejo,
  Chief Financial Officer
• Grand Pharmaceutical & Heal...,
  
• Kellie Malloy Foerter,
  Chief Operating Officer
• Holdings, Inc. Alpha,
  Director
• Brian A Leuthner,
  Interim CEO
• Robert H. Arch,
  President and CEO